Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Accumulated Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Accumulated Expenses for 10 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 21.26% to $3.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.4 million, a 21.26% decrease, with the full-year FY2024 number at $37.7 million, up 596.93% from a year prior.
  • Other Accumulated Expenses was $3.4 million for Q3 2025 at Rhythm Pharmaceuticals, down from $40.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $40.0 million in Q2 2025 to a low of $229000.0 in Q1 2021.
  • A 5-year average of $7.0 million and a median of $3.4 million in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 723.75% in 2022, then decreased 29.27% in 2025.
  • Rhythm Pharmaceuticals' Other Accumulated Expenses stood at $800000.0 in 2021, then surged by 202.38% to $2.4 million in 2022, then surged by 123.65% to $5.4 million in 2023, then soared by 596.93% to $37.7 million in 2024, then tumbled by 90.99% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Other Accumulated Expenses are $3.4 million (Q3 2025), $40.0 million (Q2 2025), and $5.8 million (Q1 2025).